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Abstract: Glaucoma is a group of optic neuropathies characterised by the degeneration of retinal
ganglion cells, resulting in damage to the optic nerve head (ONH) and loss of vision in one or both
eyes. Increased intraocular pressure (IOP) is one of the major aetiological risk factors in glaucoma,
and is currently the only modifiable risk factor. However, 30–40% of glaucoma patients do not
present with elevated IOP and still proceed to lose vision. The pathophysiology of glaucoma is
therefore not completely understood, and there is a need for the development of IOP-independent
neuroprotective therapies to preserve vision. Neuroinflammation has been shown to play a key role
in glaucoma and, specifically, the NLRP3 inflammasome, a key driver of inflammation, has recently
been implicated. The NLRP3 inflammasome is expressed in the eye and its activation is reported in
pre-clinical studies of glaucoma. Activation of the NLRP3 inflammasome results in IL-1β processing.
This pro inflammatory cytokine is elevated in the blood of glaucoma patients and is believed to
drive neurotoxic inflammation, resulting in axon degeneration and the death of retinal ganglion cells
(RGCs). This review discusses glaucoma as an inflammatory disease and evaluates targeting the
NLRP3 inflammasome as a therapeutic strategy. A hypothetical mechanism for the action of the
NLRP3 inflammasome in glaucoma is presented.
Keywords: NLRP3 inflammasome; glaucoma; RGC (retinal ganglion cells); inflammation
1. Introduction
Glaucoma is a neurodegenerative disease and the leading cause of irreversible blind-
ness worldwide. Glaucoma affects more than 70 million people, 10% of which are bilaterally
blind [1,2]. The prevalence of glaucoma is estimated to increase to 111.8 million by 2040,
which can be attributed to an aging population [3]. Glaucoma is characterised by degenera-
tion of the retinal ganglion cell (RGC) axons resulting in damage or remodelling of the optic
nerve head (ONH), as evidenced by the characteristic clinical sign of optic disc cupping [4].
These clinical manifestations lead to disruption of the visual pathway and vision loss in
one or both eyes [5]. The most common type of glaucoma is primary open-angle glaucoma
(POAG)—referred to as “glaucoma” in this review. POAG is characterised by diminished
outflow of aqueous humour (AH) despite an unobstructed or open irideocorneal angle [6].
Many patients with glaucoma present with elevated intraocular pressure (IOP > 21 mmHg);
however, this is not a requirement for the diagnosis of glaucoma, with 30–40% presenting
with normal IOP [5].
The pathophysiology of glaucoma is not well understood and, currently, IOP is the
only modifiable risk factor in the disease [7]. The goal of interventions for glaucoma
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are to lower IOP to a level that may prevent further damage to the ONH and therefore
vision loss [5–8]. Interventions include topical medications that can be applied to the
ocular surface, oral medications, laser treatment, and surgery to regulate AH outflow and
production to lower IOP [1]. However, approximately 30–40% of POAG patients exhibit a
normal IOP, indicating that elevated IOP is not the sole causative factor of glaucoma [9].
In fact a number of risk factors, such as genetics, age, and lifestyle, trigger common
pathological endpoints resulting in glaucomatous optic neuropathy [10].
Impaired axonal transport in the RGCs, observed in both animal and human studies,
is reported as a potential mechanism of damage in glaucoma [11]. Ischemia, restriction
of blood to the bodies tissues, has also been implicated in the pathogenesis of glaucoma,
with reduced ONH blood flow reported in glaucoma patients [12]. Excitotoxicity, which
results in neuron damage, has been an area of interest in the pathophysiology of glaucoma;
however, the data in this area are contradictory [5,13]. Moreover, there is an emerging body
of evidence to support the role of inflammation in glaucoma pathogenesis [14,15].
2. Inflammation in Glaucoma
A number of recent studies have investigated the role of inflammation in glau-
coma [16,17]. In experimental glaucoma, several studies reveal a significant induction
of inflammatory genes in the ONH and retina in the early stages of glaucoma [18–20].
Inflammation in glaucoma primarily occurs in the retina and ONH [21]. Common triggers
in glaucoma, such as vascular, mechanical, and immune triggers, all lead to astrocyte
and microglial reactivity, neurotrophic factor deprivation, and oxidative stress [10]. Such
cascades are believed to result in axonal damage in the ONH, which is the primary site
of injury in glaucoma [10,22]. In human and experimental models of glaucoma, activated
astrocytes [23,24] and activated microglia [25,26] are detected in the ONH, and coincide
with the increased expression of proinflammatory cytokines, such as IL-1β and TNFα,
and neurotoxic mediators, such as nitric oxide (NO), reactive oxygen species (ROS), and
glutamate [26,27]. Inflammation and oxidative stress co-exist in glaucoma, as inflammation
appears to increase the amount of oxidative stress and vice versa, creating a chronic state
of inflammation and oxidative stress [28]. ONH astrocytes in glaucoma also overexpress
cell adhesion proteins, which may promote the migration of immune cells to the site of
ONH damage, further amplifying the immune response [29].
The retina has a self-defence system consisting of microglia, astrocytes, and Müller
cells [30]. Chronic oxidative stress appears to drive inflammation through the activation of
a para-inflammatory response in the retina [28], and is believed to be a result of aging [31].
Microglia in the aging retina appear to undergo morphological changes and also increase in
number [32,33]. Para-inflammation involves low levels of inflammatory activation, which
can occur in the microglia and can contribute to damage of the retina if dysregulated
(Figure 1) [31]. A number of inflammatory cytokines involved in ageing are also found in
the glaucomatous eye [34–38]. An increase in inflammatory cytokines IFN-γ, IL-6, IL-4, IL-
10, and IL-1β resulted in a reduction of brn3a+ RGC cells in a glaucoma mouse model, and
is thought to be related to microglial activation [39]. There is also evidence of complement
activation in the glaucomatous retina [40]. The severity of RGC degeneration in glaucoma
models can be correlated with microglial activation [41]. However, it is clear that axon
degeneration and RGC death results from a system of complex interactions in glaucoma of
many different cells and mediators [10].
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Figure 1. Aging and para-inflammation contributes to retinal ganglion cell death. Ageing in the retina due to ROS is 
thought to activate a para-inflammatory response, which can become dysregulated and result in damage to the ONH and 
retina and subsequently RGC death ROS—reactive oxygen species; RG—retinal ganglion cells; ONH—optic nerve head. 
Blocking activation of microglia in an experimental glaucoma model reduced RGC 
death, further strengthening the hypothesis of glial activation and inflammation playing 
a vital role in glaucoma pathogenesis [25,42]. Targeting inflammation or immune cells as 
a therapeutic option in glaucoma appears promising. Several novel anti-inflammatory in-
hibitors have been assessed in different animal models of glaucoma, targeting different 
inflammatory markers to improve glaucoma disease pathogenesis (Table 1). These inhib-
itors alter several physical and pathophysiological measures (see Table 1). Drawbacks are 
associated with some; however, for example, oryzanol failed to control IOP in an acute 
animal model of glaucoma [43], and lutein is ineffective at reducing increased levels of 
TNFα in chronic hypoxia [44]. However, the inhibition of specific inflammatory pathways 
may prove more efficacious than the current tested non-specific inflammatory inhibitors 
[45,46]. Many anti-inflammatory therapies that specifically target pro-inflammatory cyto-
kines often experience challenges in human trials, such as increasing the risk of fatal in-
fections [47,48]. 
Therefore, there is a need to develop novel but safe anti-inflammatory therapies 
[49,50]. Recently, the nucleotide-binding oligomerization domain, Leucine rich Repeat 
and Pyrin domain containing protein 3 (NLRP3) inflammasome, has gained attention as 
a potential key orchestrator of inflammation in the aetiology of glaucoma, and may be an 
attractive therapeutic target [21,51]. 
  
Figure 1. Aging and para-inflammation contributes to retinal ganglion cell death. Ageing in the retina due to ROS is thought
to activate a para-inflammatory response, which can become dysregulated and result in damage to the ONH and retina and
subsequently RGC death ROS—reactive oxygen species; RG—retinal ganglion cells; ONH—optic nerve head.
Blocking activation of microglia in an experimental glaucoma model reduced RGC
death, further strengthening the hypothesis of glial activation and inflammation playing
a vital role in glaucoma pathogenesis [25,42]. Targeting inflammation or immune cells as
a therapeutic option in glaucoma appears promising. Several novel anti-inflammatory
inhibitors have been assessed in different animal models of glaucoma, targeting different in-
flammatory markers to improve glaucoma disease pathogenesis (T ble 1). These inhibitors
alter several physical and pathophysiological measures (see Table 1). Drawbacks are asso-
ciated with some; however, for example, oryzanol failed to control IOP in an acute animal
model of glaucoma [43], and lutein is ineffective at reducing increased levels of TNFα in
chronic hypoxia [44]. However, the inhibition of specific inflammatory pathways may
prove more efficacious than the current tested non-specific inflammatory inhibitors [45,46].
Many anti-inflam atory therapies that specifically ta get pr -inflammat ry cytokines often
experience challenges in human trials, such as increasing the risk of fatal infections [47,48].
Therefore, there is a need to develop novel but safe anti-inflammatory therapies [49,50].
Recently, the nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin
domain containing protein 3 (NLRP3) inflammasome, has gained attention as a potential
key orchestrator of infla mation in the aetiology of glaucoma, and may be an attractive
therapeutic target [21,51].
Biomolecules 2021, 11, 1239 4 of 14
Table 1. Anti-inflammatory inhibitors tested in several in-vivo models of glaucoma.
Inhibitor of
Inflammatory Markers Inflammatory Markers Glaucoma Model In-Vivo Findings References
γ-Oryzanol TNF-α and IL-6
Subconjunctival
injection of phenol in
rabbit
Reduces IOP in a chronic glaucoma
model by inhibiting the induction of
TNF-α and IL-6, and provides
protection against glaucoma
[43]




No effect on IOP. Prevents RGC
death and axon degradation.
Reduces microglial activation and
inhibits induction of inflammatory
cytokines and chemokines.
[52]
Myricetin IL-1α, IL-1β, IL-6, andTNF-α
Injection of hyaluronic
acid into the anterior
chamber of the eye in
Dawley rats
Lowers IOP level in animals and
reduces inflammatory marker levels
in in vitro experiments.
[46]
Lutein
(hydroxycarotenoid) TNF-α and IL-1β
Mouse model of retinal
ischemia
Modulates the overexpression of
GFAP in in vivo models of retinal
ischemia and inhibits overactivation
of NF-κB, IL-1β, and Cox-2 in
Müller cells.
[44]
Puerarin IL-1β, IL-17A, andTNF-α
Neovascular glaucoma
in C57BL/6 mice
Puerarin reduces high levels of
IL-1β, IL-17A, and TNF-α in animal
models of glaucoma. It also
maintains reactive oxygen species,
superoxide dismutase and
malondialdehyde, NOS, and
inducible NOS and NF-κB to an
optimum level.
[45]
IOP—intraocular pressure; RGCs—retinal ganglion cells; NOS—neuronal nitric oxide synthase; GFAP—glial fibrillary acidic protein;
IOP—intraocular pressure; RGC—retinal ganglion cell; NF-κβ—nuclear factor-kappa beta; IL—interluekin; TNF-α—tumour necrosis
factor-alpha; Cox-2—cyclooxygenase 2; NOS—nitric oxide synthases.
3. The NLRP3 Inflammasome
Pattern recognition receptors (PRRs) recognise danger signals, such as, pathogen asso-
ciated molecular patterns (PAMPs) and danger associated molecular patterns (DAMPs) [53].
Nod like receptors (NLRs) are a type of PRR with a nucleotide-binding and oligomerisa-
tion domain, and act as receptors in the cytoplasm [50]. NLRs are categorised into four
subgroups based on their N-terminal domain, with the NLRP group containing a pyrin
domain [54]. NLRP3 is one member of the NLRP family, of which there are 14 members,
all of which are involved in the formation of inflammasomes [55]. NLRP3 is the most well
characterised member of the inflammasome family [56], and is an important regulator of
inflammatory diseases and plays a key role in the innate immune system [57].
The NLRP3 inflammasome (NOD-, LRR-, and pyrin domain-containing protein 3) is
an intracellular, multiprotein signalling complex implicated in a plethora of inflammatory
diseases [55]. These integral elements include the sensor NLRP3 protein, an adaptor protein
called adaptor molecule apoptosis-associated speck-like protein containing a CARD (ASC)
and procaspase-1 [58]. The sensor NLRP3 protein can be triggered by PAMPs, DAMPs,
and a range of diverse external stimuli such as infection and injury. NLRP3 inflammasome
activation is a tightly regulated system and requires two signals for activation, as depicted
in Figure 2. The priming signal results in an increased expression of NLRP3, pro-IL-1β,
and pro-IL-18, as the nuclear factor-kappa beta (NF-κβ) pathway is activated in response
to a stimulus [58]. The priming step of inflammasome activation is tightly controlled by a
series of different post translational modifications of NLRP3, ASC, and caspase-1, including
ubiquitination, phosphorylation, and sumoylation [59].
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Figure 2. Hypothetical mechanism for the role of NLRP3 in glaucoma. Activation of the NLRP3
inflammasome requires two signals for activation. Signal 1 results in transcriptional upregulation of
Pro-IL-1β and NLRP3 protein via the NF-κβ pathway. Stress to the ONH is thought to activate the
NF-κβ pathway. Signal 2 results in the oligomerisation of ASC, NLRP3, and pro-caspase-1 to form the
NLRP3 inflammasome. NLRP3 inflammasome oligomerisation results in cleavage of pro-caspase-1
into active caspase-1, which can in turn cleave pro-IL-1β into IL-1β, which can leave the c ll to
drive inflammatio . ROS or extracellular ATP are proposed to resul in inflammasome olig meri
sation in glaucoma. ONH—optic nerve head; ROS—reactive oxygen species; ATP—ad nosine
triphosphate; RGC—retinal ganglion cell; DAMPS—danger associated molecular patterns; IL-1β—
interluekin-1beta; ASC—apoptosis-associated speck-like protein containing a caspase-recruitment
domain; NLRP3–-NLR family pyrin domain containing 3; NF-κβ—nuclear factor-kappa beta.
Triggering or activation is the second signal needed for inflammasome activation, and
involves the oligomerisation of NLRP3 in its inactive form with procaspase-1 and ASC.
Generally the activation step of inflammasome oligomerisation is a result of potassium
efflux from the cell [59]. This results in the cleavage of procaspase-1 into caspase-1 and, as a
result, pro-IL-1β and pro-IL-18 into active IL-1ß and IL-18, which are subsequently secreted
from the cell [60,61]. As w ll as producing pro-infla matory cytokin s, active caspase-1
also r sults in the cleav ge of gasdermi -D (GSDMD), a pore forming protein, re ulting
in pyroptosis, a form of cell death [62]. In the chronic disea es driven by inflammation,
such as type 2 di b tes and cryopyrin-associated periodic syndrom (CAPS), the NLRP3
inflammasome is dy regulated, resulting in the uncontrolled elease of o-inflammatory
cyt kine IL-1β, which drives inflammation in such diseases [63,64].
4. IL-1 Signaling in the Eye
Interleuk 1 receptor 1 (IL-1R1) m diates interleukin 1 (IL-1) (IL-1α and IL-1β) signal-
ing. De pite many studies al uding to the activation of microglia by IL-1, there is conflicting
evidence in the literature that suggests that microglia do not express IL-1R1 [65]. However,
IL-1R1 is clearly expressed in endothelial cells, astrocytes, and neurons in the ye [66].
IL-1α and IL-1β have been detected in various parts of the eye, including in tear fluid and
corneal epithelial cells [67]. In the brain, IL-1 stimulates endothelial IL-1R1, which then
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produces factors that drive microglial inflammatory gene expression [68]. This process may
also happen in the retina, as IL-1-stimulated inflammatory cytokine expression was largely
abolished after the depletion of microglia, but the restoration of IL-1R1 on endothelial,
but not microglial, cells restored IL-1 induced inflammatory gene expression [66]. Retinal
pigment epithelial cells and the trabecular meshwork of humans also express IL-1R1 [69].
Fibroblasts are also known to highly express IL-1R1, and may contribute to microglial
stimulation. Fibrosis is a known pathological response in the lamina cribrosa in glau-
coma [70,71], and it is likely that there is a cross talk between the lamina cribrosa and
retinal cells, which ultimately leads to the activation of microglial cells and subsequent
RGC death [65,72].
5. NLRP3 in the Eye
The NLRP3 inflammasome is constitutively expressed in various parts of the eye
including the retinal pigment epithelium and ONH astrocytes in both human and mice,
indicating the importance of this mediator in the defense system of the eye [73–75]. NLRP3
is also expressed in many other cells of the eye, including the ONH, retinal microglia,
Müller cells [76–78], and astrocytes [78,79]. NLRP3 expression is not limited to the retina
and ONH, and is found throughout the eye in the conjunctiva, trabecular meshwork, retinal
pigment epithelium, and corneal epithelial cells in disease states [80–84].
6. The NLRP3 Inflammasome in Glaucoma
Dysregulation of the NLRP3 inflammasome has been implicated in several neurode-
generative diseases, including Alzheimer’s disease and multiple sclerosis [85]. Increased
levels of IL-1β mRNA and protein have also been observed in the blood of glaucoma
patients compared with controls, suggesting activation of the NLRP3 inflammasome in
glaucoma [35]. Furthermore, activation of the NLRP3 inflammasome has been associated
with the induction of IL-1β and death of RGCs in mouse models of acute glaucoma via
optic nerve (ON) crush. [64,86]. In an inducible mouse model of glaucoma, the use of
fluorescent reporter mice to track inflammasome activation demonstrated that NLRP3
inflammasome activation occurs early in the ONH, following IOP elevation, and coincides
with the induction of pro-inflammatory cytokines and Iba1+, a microglia marker, immune
cells in the ONH [87]. This upregulation of inflammatory genes occurs as early as 7 days
post IOP elevation in the ONH and before the induction of inflammatory genes occurs in
the retina [79]. With the use of knockout mice lacking various components of the NLRP3
inflammasome, we can conclude that the NLRP3 inflammasome activation is required for
RGC death [64,79,88]. These studies support the hypothesis that “danger” signals in the
eye, IOP elevation being one, activates the NLRP3 inflammasome pathway in the glial
cells of the ONH and retina, resulting in neurotoxic inflammation, axon degeneration, and
subsequent death of RGCs in glaucoma models.
7. Proposed Mechanism for the Role of NLRP3 in Glaucoma
Chronic inflammation from unknown causes, ageing, or genetics may be initiating
factors [1], and may directly lead to the activation of glial cells or, alternatively, may
lead to damage to the trabecular meshwork [89]. NLRP3 is expressed and activated in
the trabecular meshwork as a result of oxidative stress, leading to elevated IOP, further
exacerbating the initiation of inflammation [80,90].
Initial injury may also be due to increased IOP resulting in mechanical stress on
various cells such as fibroblasts in the sclera [91,92], and subsequently or alternatively,
lamina cribrosa astrocytes of the ONH. Fibroblasts and astrocytes are known to express
high levels of IL-1R1, and the NLRLP3 inflammasome is known to be activated in these
cell types [65,78,93–95].
A number of risk factors trigger common pathological endpoints resulting in glauco-
matous optic neuropathy [10]. In glaucoma, the ON glial cells become activated, which in
turn damage the axons leaving the eye and further trigger inflammatory cell recruitment
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to the injury sites [79,96]; ONH astrocytes constitutively express NLRP3 and injury to
the ONH may also activate the NLRP3 inflammasome pathway in these cells [79,96]. As
Figure 2 depicts, the NF-κβ pathway is activated by DAMPs or injury to the ON, resulting
in transcriptional upregulation of pro-IL-1β and NLRP3 [58]. A second signal, generally
resulting in potassium efflux from the cell, results in the oligomerisation of NLRP3, ASC,
and pro-caspase-1 to form the inflammasome complex [30,59]. We hypothesise that extra-
cellular ATP binding to the ligand-gated ion channel purinergic type 2 receptor 7 (p2x7r) or
ROS produced by oxidative stress as a result of ageing are some methods of inflammasome
activation in glaucoma that may be independent of IOP [30,76,97]. The ATP concentration
is higher in the aqueous humour of glaucoma patients compared with the controls, and
increased levels of ATP in the glaucomatous eye are thought to be released from cells
damaged or stressed by elevated IOP [98–100]. However, sheer stress and cell swelling
in tissues can also increase extracellular ATP in the absence of elevated IOP [101,102].
Moreover, it has been proposed that ROS produced from reactive astrocytes contribute
to early axonal damage within the ONH in glaucoma [103]. Amyloid beta, a known in-
flammasome activator in the brain microglia, is also increased in the glaucomatous eye
compared with normal eyes, and may result in retinal glial cell activation [104,105]. TGF-β,
a profibrotic cytokine is found in the aqueous humour and ONH astrocytes in glaucoma
patients. TGF-β is involved in damage to the ONH in glaucoma [106] and TGF-β can
induce activation of the NLRP3 inflammasome, which has also been demonstrated to be
involved in fibrosis [107]. Upon inflammasome activation, pro-caspase-1 is cleaved into
its active form caspase-1, which can in turn cleave pro-IL-1β into its active form IL-1β,
which is then secreted from the cell [61]. In glaucoma, IL-1β was found to be one of the
first inflammatory cytokines upregulated in the ONH, and is a powerful stimulus for
immune cell recruitment, further supporting the role of neurotoxic inflammation as a
significant contributor to the neurodegenerative process of glaucoma [108,109]. Therefore,
pharmacologically targeting NLRP3 may serve as a neuroprotective therapy to prevent the
progression of glaucoma.
8. NLRP3 Inflammasome as a Target for Therapy in Glaucoma
There is an obvious need for the development of new medications for glaucoma,
given that current treatments work to lower IOP only. However, these treatments are not
successful in all patients [110,111]. NLRP3 may be a promising IOP independent target
for the treatment of glaucoma [112]. Several studies demonstrate that the inhibition of
NLRP3 activation significantly inhibits the death of RGCs in experimental models of retinal
ischemia/reperfusion injury (acute glaucoma) [113–116]. Blockade of the P2x7r, which can
act as signal 2 in inflammasome activation with A438079, a P2x7r inhibitor, also attenuates
RGC death by inhibiting inflammasome activation. Additionally in an in-vitro model, ATP,
which binds to the P2x7r, was shown to induce inflammation in the retina by activating the
NLRP3 inflammasome [76]. High-mobility group box 1 (HMGB1), which is often released
from damaged cells, is known to be released upon rapid IOP elevation and is also a known
DAMP that activates Toll Like Receptor 4 (TLR-4) to activate the NF-kB pathway. In an
acute glaucoma mouse model, the release of HMGB1 resulted in increased levels of NLRP3
and IL-1B. Inhibition of HMGB1 resulted in reduced NLRP3 and IL-1B levels, which also
reduced RGC death and glaucoma severity [117].
However, in the more clinically relevant microbead-induced mouse model of glau-
coma, where IOP was elevated, treatment with a commercially available NLRP3-specific
inhibitor (MCC950) [118] was also shown to prevent axon degeneration and death of
RGCs [119]. In this microbead-induced model of glaucoma, 4 weeks of elevated IOP re-
sulted in a 25–30% loss of RGCs, which was significantly attenuated following a three-times
a week treatment with intraperitoneal MCC950. Mice treated with MCC950 displayed
axon and RGC densities equal to that of the non-glaucoma controls. MCC950 injection,
however, had no effect on IOP elevation in the treated mice [119]. Currently, this is the
only study that has evaluated a NLRP3-specific inhibitor in an inducible model of glau-
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coma [119]. Collectively, these studies provide evidence that NLRP3 inhibition may be a
novel therapeutic strategy to protect RGCs and prevent axon degeneration in glaucoma.
MCC950, a small molecule drug, however, does present with some drawbacks, in-
cluding the very short half-life of MCC950 of only 3 h [120]. This means the drug must
be administered regularly either systemically or by multi-intravitreal injections, both of
which are not desirable for diseases of the eye. Other limitations of small molecule in-
hibitors include that they are often not fully characterised, and many are not completely
specific to their targets [121,122]. Therefore, there has been interest in recent years in the
development of biologics, such as antibodies for the treatment of many chronic conditions,
as they have revolutionised the treatment and modification of many diseases including
some cancers and autoimmune rheumatic diseases [121,122]. Biologics are well known to
have a longer half-life, allowing for longer dosing intervals because of their larger size,
which is an important factor in the treatment of glaucoma [122,123]; they are also recy-
cled by the body and have a high affinity and potency. The major advantage of biologic
molecules for treatment is the specificity of their mechanisms of actions preventing off
target effects [122]. Financial cost in the long run is also an advantage of biologic therapies,
as they are expected to deliver a better economic return than small molecules [121]. The
use and approval of biologics in medicine is increasing each year, targeting extracellular
or cell membrane proteins [123]. However, the delivery mechanisms of antibodies into
cells to target intracellular molecules is a major obstacle [123]. The current inhibitors of
NLRP3 and IL-1β are outlined in Table 2. It is important to note that, generally, biologics
targeting the NLRP3/IL-1β pathway target secreted IL-1β directly, like Canakinumab to
suppress its inflammatory responses, which poses a serious risk of fatal infection, as IL-1β
cannot be produced in response to an infection [49]. Targeting NLRP3 to supress IL-1β
production means IL-1β can still be produced by other pathways if the body encounters
an acute infection [124]. Anakinra is another biologic that targets the NLRP3 pathway
binds to IL-1R1 to inhibit IL-1β binding to IL-1R1, as this can further activate the NLRP3
inflammasome [125]. There is a number of small molecule inhibitors that target NLRP3 to
suppress its effects or inhibit NLRP3 inflammasome oligomerisation [114,126–129].
Table 2. Novel IL-1β and NLRP3 inhibitors.
Inhibitors Type Mechanism of Action Reference
Canakinumab Biologic Inhibits binding of IL-1β to IL-1R1 [49]
Anakinra Biologic Binds to IL-1 receptor to inhibit IL-1β binding [125]
MCC950 Small molecule Inhibits caspase-1 activation by binding to NLRP3 [126]
CY-09 Small molecule Inhibits NLRP3 ATPase activity by binding to the ATP-bindingmotif of the NACHT domain [127]
Tranilast Small molecule Suppresses NLRP3 assembly by binding to NACHT domain [128]
IC-100 Biologic Inhibits adaptor ASC [130]
Argablin Small molecule Inhibits NLRP3 activation (specific mechanism not known) [129]
Cholchicine Small molecule Inhibits expression of components of NLRP3 [113]
IL-1β—interleukin-1beta; IL-1R1—interleukin 1 receptor 1; NLRP3—NLR family pyrin domain containing 3; ATP—adenosine triphosphate;
NACHT—a central nucleotide-binding and oligomerization domain; ASC—Apoptosis-associated speck-like protein containing a caspase-
recruitment domain.
9. Conclusions
Elevated IOP is the only modifiable risk factor in glaucoma, and IOP lowering ther-
apies are unsuccessful in many patients. There is a need for IOP independent therapies
to treat or slow glaucoma progression. There is significant evidence to support the role of
inflammation in the pathogenesis of glaucoma. In particular, the NLRP3 inflammasome
pathway in glial cells of the ONH and retina appears to play a critical role in axon degen-
eration and death of RGCs in glaucoma. The NLRP3 inflammasome therefore appears to
Biomolecules 2021, 11, 1239 9 of 14
be a strong target for therapy development in glaucoma. A biologic therapy with a long
dosing interval would be desirable to avoid multiple dosing. Additional studies are now
required to further investigate current and novel inhibitors of the NLRP3 inflammasome
pathway for glaucoma treatment.
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